About nemolizumab
Interleukin-31 receptor alpha antagonist
Used for
- Moderate-to-severe atopic dermatitis in eligible adults and adolescents
- Prurigo nodularis in adults
Usual adult dose
Atopic dermatitis: 60 mg under the skin initially, then 30 mg every 4 weeks. Prurigo nodularis: 60 mg initially, then 30 mg every 4 weeks.
Usual dose in children
Atopic dermatitis: for ages 12 years and older, 60 mg initially, then 30 mg every 4 weeks. Not established for younger children.
Common side effects
- Headache
- Joint pain
- Hives or other allergic reactions
- Injection-site reactions
Important warnings
- Serious allergic reactions can occur; stop treatment and seek urgent care for breathing difficulty or facial swelling.
- Avoid live vaccines during treatment.
- Treat existing helminth infections before starting; discontinue if infection does not respond to treatment.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether nemolizumab passes into breast milk; consider benefits of breastfeeding and treatment.
Interactions
- Live vaccines may be less safe or effective during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.